Issue published 30 December 2025 Abstract Background: To determine whether initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months of type 2 diabetes (T2DM) diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index (BMI)
This discussion and other parts of this Annual Report contain forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements of our plans, objectives, expectations, intentions, forecasts and projections
Central to the plaintiffs argument is the claim that these medications cause gastroparesis, a serious gastrointestinal condition
J Pathol 238:401411 Craven N (1986) Chemotactic factors for bovine neutrophils in relation to mastitis
GLP-1 medications also slow gastric emptying, which can worsen acid reflux in some people, bringing acid into contact with teeth even without vomiting
Before starting Ozempic, Vieira said she usually had a time in range of 70-80% and now its around 80-90% with fewer lows since she needs less insulin
